Key result
The potential for a rebound pro-thrombotic effect after discontinuing dabigatran and other newer anticoagulants remains a subject of debate.
Why the study?
Does discontinuing dabigatran cause a rebound in thrombotic events?
Does discontinuing dabigatran cause a rebound in thrombotic events?
The text highlights concerns regarding potential rebound pro-thrombotic activity following the discontinuation of newer anticoagulants such as dabigatran and rivaroxaban.
The REMODEL trial has suggested that stopping dabigatran does not produce a rebound thrombotic effect.1 2 However, others have raised the possibility of this.3 Such rebound pro-thrombotic activity and clusters of thrombotic events have been reported with heparin and older anti-thrombotic drugs, and concerns are now being expressed about the newer anticoagulants, including the factor Xa inhibitor, rivaroxaban, and oral direct thrombin …
No takes yet. Share an insight, caveat, or question.
Thorne et al. (2012) conducted a letter in Thrombotic events. Discontinuing dabigatran was evaluated. The potential for a rebound pro-thrombotic effect after discontinuing dabigatran and other newer anticoagulants remains a subject of debate.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: